CDEK
← All drugs Report issue

asm-024

Small moleculeexperimental

Clinical trial activity

4 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2010 (NCT01092403)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Mechanism of action

  • Neuronal acetylcholine receptor; alpha3/beta4ANTAGONIST

    Neuronal acetylcholine receptor; alpha3/beta4 antagonist

    ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called "a7 silent agonist": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci

  • Muscarinic acetylcholine receptor M3ANTAGONIST

    CHRM3 antagonist

    ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called "a7 silent agonist": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci

  • Muscarinic acetylcholine receptor M1ANTAGONIST

    CHRM1 antagonist

    ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called "a7 silent agonist": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci

  • Muscarinic acetylcholine receptor M2ANTAGONIST

    CHRM2 antagonist

    ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called "a7 silent agonist": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596. (A minimal pharmacophore for a nicotinic alpha7 silent agonist, relevance for the therapeutic development of treatments for asthma Poster#: 224.06/C24. Neuroscience Meeting Planner. New Orleans, LA: Soci

  • Neuronal acetylcholine receptor protein alpha-7 subunitMODULATOR

    CHRNA7 modulator

    ASM-024 displays both antagonistic and agonistic activity on CHRNA7, is thought to be a so called "a7 silent agonist": produce little or no CHRNA7 channel activation on its own but effectively activate the ion channel when combined with the type II positive allosteric modulator (PAM) PNU-120596.

Chemistry & pharmacology

Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • asm-024
  • asm-024
  • asm-024

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01855230Phase 2Aug 1, 2013Asmacure Ltée
NCT01793298Phase 1/Phase 2 (Phase 2)Mar 1, 2013Asmacure Ltée
NCT01190826Phase 2Aug 1, 2010Asmacure Ltée, SFBC Anapharm
NCT01092403Phase 2Apr 1, 2010Asmacure Ltée
Showing 4 of 4 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Asmacure LtéeAcademic/Hospital4412010
SFBC AnapharmFor profit1012010
2 organizations
Page 1 / 1